RG6501 (OpRegen) Phase 1/2a Clinical Results to Be Presented at 2023 Retinal Cell and Gene Therapy Innovation Summit

Lineage Cell Therapeutics announced that results from a phase 1/2a clinical study of RG6501 (OpRegen), will be presented at the 2023 Retinal Cell and Gene Therapy Innovation Summit, organized by the Foundation Fighting Blindness and the Oregon Health & Science University Casey Eye Institute. The meeting will be held April 21, 2023, at the Marriott New Orleans Warehouse Arts District in New Orleans. The presentation, “Phase 1/2a Study of OpRegen in Patients with Geographic Atrophy (GA),” will be presented by Eyal Banin, MD, PhD, Director, Center for Retinal and Macular Degenerations (CRMD), Department of Ophthalmology at Hadassah-Hebrew University Medical Center.

RG6501 (OpRegen) is a retinal pigment epithelium cell transplant therapy currently in development for the treatment of geographic atrophy secondary to age-related macular degeneration (AMD). It is being developed under an exclusive worldwide collaboration between Lineage, and Roche and Genentech, and is currently being evaluated in a phase 2a clinical study in patients with geographic atrophy secondary to age-related macular degeneration (ClinicalTrials.gov Identifier: NCT05626114).

The 2023 Retinal Cell and Gene Therapy Innovation Summit, "Defining the Preclinical to Clinical Roadmap," will feature presentations that emphasize clinical trial design for gene and cell-based therapies. Representatives from the biotech and pharma industries will come together with physicians and scientists to discuss rapidly emerging ocular gene and cell therapies and strategize how to move the most advanced retinal disease therapy options forward.